DENVER, Nov. 2, 2015 /PRNewswire/ -- United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
The company has also filed a PCT application for pursuing international patents.
United Cannabis' research team has identified unique ratios and specifications of cannabinoids that may be used to target the underlying mechanisms of disorders such as insomnia, anxiety, neuropathy, Crohns disease, seizures, and cancer.
The patent application identifies a matrix system for categorizing CBD & THC rich strains with specific terpene profiles into accurately dosed delivery methods for both inactive and active cannabinoids. The patent application includes a wide range of extraction methods including a plant fat delivery system of the medicine. The delivery methods include: capsule, sublingual, and topical.
Tony Verzura, United Cannabis' Chief Technology Officer, commented, "We continue our march forward into the future of cannabis-based medicine. We have made great progress with the optimum delivery methods and combinations of cannabinoids that provide the greatest benefit to the patient. This next step in our patent application process brings us closer to providing cannabis-based solutions for a broad range of ailments."
Earnest Blackmon, United Cannabis' Chief Executive Officer, commented, "We are excited to continue working on developing and improving products as well as patient support services through our Advanced Cannabinoid Therapy program (A.C.T. Now Program). We look forward to fostering long term relationships with qualified licensed centers in states with compliant regulatory structures."
About United Cannabis Corporation
United Cannabis Corporation was formed to advance the use of cannabinoids in medicine through research, product development and education. The Company is dedicated to improving the lives of patients through the creation of products using only the highest quality genetics, purest extractions and most effective protocols possible. The Company's A.C.T. Now Program and patent-pending Prana Bio Nutrient Medicinals provide a comprehensive solution designed to enable physicians and patients to design, implement and monitor effective therapy protocols.
For further information, please visit www.unitedcannabis.us
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE United Cannabis Corporation